Medical journal retracts Tavneos pivotal paper amid wider regulatory clampdown

The retraction further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny. This further weakens Amgen’s case for Tavneos’ continued use on the market as the drug comes under intense regulatory scrutiny. The New England Journal of Medicine has retracted Tavneos’ pivotal study paper upon request of two academic authors associated with it. Credit: Grand Warszawski / Shutterstock.com. In another blow to the future market prospects of Amgen’s rare disease therapy, Tavneos (avacopan), the New England Journal of Medicine (NEJM) has retracted the drug’s pivotal study paper. This comes after two…

Source: Clinical Trials Arena